Press releases

2011-10-31

Innovacell presents at congress in London

Innovacell Biotechnologie AG today has announced to be one of the presenters at the upcoming Commercial Translation of Regenerative Medicine Congress in London from November 14th - 16th.

The three-day conference will feature a hybrid of business, regulatory and scientific topics. The speakers will be drawn from pharmaceutical and biotech companies, such as regulators and cell and gene therapy developers.

Ekkehart Steinhuber, Innovacell’s CEO, will be presenting Innovacell’s clinical trial results of the Phase IIb trial for ICES13, a product for treating stress urinary incontinence. The study was carried out in 32 centers in four European countries. A Phase III trial is already approved by authorities and will start in the fourth quarter of 2011. The session will focus on the technology of the ultrasound guided injection device and the results of the Phase IIb trial. The trial, begun in 2010, is a randomized, partly double-blind, placebo-controlled, multi-center trial involving 280 patients.

The company hopes to capitalize by providing a better quality of life for the more than two million new female patients per annum in the seven major markets. This target group suffers from stress urinary incontinence for which the treatment with ICES13 would be the treatment of choice.

About Innovacell Biotechnologie AG

Innovacell Biotechnologie AG is a privately held biotechnology company based in Innsbruck, Austria. The Company is engaged in the clinical development and commercialization of autologous (patients’ own), minimally invasive, potentially curative (“once-in-a-life-time”) cell therapies to re-establish functionality of sphincter muscle in patients with stress urinary incontinence (SUI) or fecal incontinence (FI). The Company is lead by an experienced management team, owns and operates one of Europe’s largest, state-of-the-art GMP facilities.

ICES13 for SUI patients is currently in late-stage clinical development (Phase III) and ICEF15 for persons with FI is in mid-stage testing (Phase IIa). Each product comprises an autologous myoblast cell suspension that is implanted by means of two different, specifically designed, proprietary and CE-marked injectors.

Press contact